BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...
Most cases of squamous cell carcinoma can be cured when found early and treated properly. Today, many treatment options are available, and most are easily performed at a doctor’s office. Which ...
1d
The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...
A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...
Surgical, radiation and medical oncologists in the Baylor St. Luke's Medical Center Dan L Duncan Comprehensive Cancer Center specialize in the diagnosis and treatment of head and neck squamous cell ...
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous ...
No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...
Surgery is a common treatment for non-melanoma skin cancers (NMSCs), including both basal cell cancers and squamous cell cancers. If the skin cancer is a simple lesion that’s easily treatable ...
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Incyte (NASDAQ:INCY) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback